<DOC>
	<DOC>NCT02822326</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of chimeric antigen receptor 19 (CD19-CAR-T2 Cells) infusions in patients with chemotherapy resistant or refractory CD19+ acute Leukemia.</brief_summary>
	<brief_title>Phase I Study of CD19-CAR-T2 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Acute Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<criteria>Patient with relapsed and/or refractory CD19 positive Bcell acute leukemia Eastern Cooperative Oncology Group (ECOG) performance status 《 3 ALT/ AST 《 3x normal Bilirubin &lt; 2.0 mg/dl Creatinine &lt; 2.5 mg/dl and less than 2.5x normal for age LVEF》 45% Accept white blood cell collection Provide informed consent Previous treatment with investigational gene or cell therapy medicine products Solitary extramedullary relapse Active hepatitis B , hepatitis C or HIV infection Uncontrolled active infection Presence of grade 24 acute or extensive chronic GVHD Active CNS involvement: epilepsy, paresis, aphasia, stroke, severe head trauma, Dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, uncontrolled mental illness, etc. Any uncontrolled active medical disorder that would preclude participation as outlined. Received nondiagnostic purposes major surgery within the past 4 weeks Participated in any other clinical study within the past 4 weeks Used murine biological products (except blinatumomab), unless it is proved no antimouse antibodies exist. Pregnancy or breastfeeding women Use of prohibited drugs: Steroids: Therapeutic doses of steroids must be stopped &gt; 72 hours prior to CD19CART2 Cells infusion Allogeneic cellular therapy: Any donor lymphocyte infusions (DLI) must be completed &gt; 4 weeks prior to CD19CART2 Cells infusion GVHD therapies: Any drug used for GVHD must be stopped &gt; 4 weeks prior to CD19CART2 Cells infusion Chemotherapy: i. The following drugs must be stopped &gt; 1 week prior to CTL019 infusion and should not be administered concomitantly or following lymphodepleting chemotherapy: hydroxyurea, vincristine, 6mercaptopurine, 6thioguanine, methotrexate &lt;25 mg/m2, cytosine arabinoside &lt; 10 mg/m2/day, asparaginase; ii. The following drugs must be stopped &gt; 4 weeks prior to CTL019 infusion: salvage chemotherapy (e.g. clofarabine, cytosine arabinoside &gt; 100 mg/m2, anthracyclines, cyclophosphamide), excluding the required lymphodepleting chemotherapy drugs Any situation that may increase the risk of the test or interfere with the test results</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>CART CD19</keyword>
	<keyword>Chemotherapy Resistant</keyword>
	<keyword>Chemotherapy Refractory</keyword>
	<keyword>CD19 +</keyword>
	<keyword>Lymphoma</keyword>
</DOC>